tradingkey.logo
tradingkey.logo
Search

Shuttle Pharmaceuticals Holdings Inc

SHPH
Add to Watchlist
3.250USD
0.0000.00%
Close 06/30, 16:00ETQuotes delayed by 15 min
1.80MMarket Cap
294.12P/E TTM

TradingKey Stock Score of Shuttle Pharmaceuticals Holdings Inc

Currency: USD Updated: 2026-06-29

Key Insights

Shuttle Pharmaceuticals Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 219 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Shuttle Pharmaceuticals Holdings Inc's Score

Industry at a Glance

Industry Ranking
219 / 387
Overall Ranking
414 / 4570
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Shuttle Pharmaceuticals Holdings Inc Highlights

StrengthsRisks
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is 294.12, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 110.92K shares, decreasing 33.20% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.53.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Shuttle Pharmaceuticals Holdings Inc?

The TradingKey Stock Score provides a comprehensive assessment of Shuttle Pharmaceuticals Holdings Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Shuttle Pharmaceuticals Holdings Inc’s performance and outlook.

How do we generate the financial health score of Shuttle Pharmaceuticals Holdings Inc?

To generate the financial health score of Shuttle Pharmaceuticals Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Shuttle Pharmaceuticals Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Shuttle Pharmaceuticals Holdings Inc.

How do we generate the company valuation score of Shuttle Pharmaceuticals Holdings Inc?

To generate the company valuation score of Shuttle Pharmaceuticals Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Shuttle Pharmaceuticals Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Shuttle Pharmaceuticals Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Shuttle Pharmaceuticals Holdings Inc.

How do we generate the earnings forecast score of Shuttle Pharmaceuticals Holdings Inc?

To calculate the earnings forecast score of Shuttle Pharmaceuticals Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Shuttle Pharmaceuticals Holdings Inc’s future.

How do we generate the price momentum score of Shuttle Pharmaceuticals Holdings Inc?

When generating the price momentum score for Shuttle Pharmaceuticals Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Shuttle Pharmaceuticals Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Shuttle Pharmaceuticals Holdings Inc.

How do we generate the institutional confidence score of Shuttle Pharmaceuticals Holdings Inc?

To generate the institutional confidence score of Shuttle Pharmaceuticals Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Shuttle Pharmaceuticals Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Shuttle Pharmaceuticals Holdings Inc.

How do we generate the risk management score of Shuttle Pharmaceuticals Holdings Inc?

To assess the risk management score of Shuttle Pharmaceuticals Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Shuttle Pharmaceuticals Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Shuttle Pharmaceuticals Holdings Inc.
KeyAI